Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical firm based in Needham, Massachusetts, dedicated to developing innovative immunotherapies for cancer patients. Its pipeline features CAN-2409, which is presently in Phase II clinical trials for pancreatic and lung cancers, and has progressed to Phase III for prostate cancer. This therapy also successfully completed Phase Ib/II trials for high-grade glioma. Furthermore, the company is advancing CAN-3110, an investigational therapy currently in Phase I clinical trials for recurrent glioblastoma. Established in 2003, the company operated as Advantagene, Inc. until November 2020, when it rebranded as Candel Therapeutics, Inc.
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | $125.00K | $125.00K | $125.00K | $125.00K |
| Cost of Revenue | $990.00K | $23.98M | N/A | $14.59M | N/A | $6.61M |
| Gross Profit | $-990.00K | $-23.98M | $125.00K | $-14.47M | $125.00K | $-6.48M |
| Gross Margin | 0.00% | 0.00% | 100.00% | -11575.20% | 100.00% | -5185.60% |
| Operating Expenses | $32.38M | $14.41M | $34.85M | $11.26M | $13.94M | $2.56M |
| Operating Income | $-33.37M | $-38.39M | $-34.72M | $-25.73M | $-13.81M | $-9.04M |
| Operating Margin | 0.00% | 0.00% | -27777.60% | -20580.80% | -11048.00% | -7229.60% |
| Net Income | $-55.18M | $-37.94M | $-18.79M | $-36.12M | $-17.68M | $-8.24M |
| Net Margin | 0.00% | 0.00% | -15035.20% | -28899.20% | -14144.00% | -6592.00% |
| EPS (Basic) | $-1.74 | $-1.31 | $-0.10 | $-1.26 | $-1.18 | $-0.43 |
| EBITDA | N/A | N/A | N/A | N/A | N/A | N/A |
| Stock Option Compensation Expense | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Earnings Ratio | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Sales Ratio | N/A | N/A | N/A | N/A | N/A | N/A |
| Shares Outstanding | N/A | N/A | N/A | N/A | N/A | N/A |
| Market Capitalization | N/A | N/A | N/A | N/A | N/A | N/A |